The FDA’s approval of Amgen’s DLL3 × CD3 bispecific antibody tarlatamab (Imdelltra) last year validated the DLL3 cancer target, demonstrating its approvability in extensive-stage small-cell ...
Center for Optoelectronic Materials and Devices, School of Polymer Science and Engineering, The University of Southern Mississippi, Hattiesburg, Mississippi 39406, United States ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback